Table 5.
Breakthrough severe COVID-19 of the SARS-CoV-2 Delta variant by cohort studies.
| Type of disease | Age (year) | Weeks post final vaccination | No. of studies | P h/I 2 (%) | Incidence per 100 person years (95% CI) | RR (95% CI) | P | Vaccine name |
|---|---|---|---|---|---|---|---|---|
| Severe COVID-19 | ≥18 | ≥ 2 | 10 | <0.001/98.7 | 0.1 (0.0, 0.1) | NA | NA | mRNA-1273; BNT162b2; Ad26.COV2.S |
| 2-18 | 4 | <0.001/94.6 | 0.0 (0.0, 0.0) | Ref | Ref | |||
| 18-26 | 2 | 0.003/88.7 | 0.1 (0.0, 0.1) | 8.8 (7.1, 10.9) | <0.001 | |||
| 26-33 | 0.292/10.1 | 0.2 (0.2, 0.3) | 21.4 (17.1, 26.8) | <0.001 | ||||
| ≥ 33 | <0.001/84.8 | 0.4 (-0.0, 0.8) | 56.3 (44.6, 71.1) | <0.001 | ||||
| ≥18 | ≥ 2 | 15 | <0.001/98.2 | 0.1 (0.1, 0.1) | NA | NA | mRNA-1273; BNT162b2 | |
| 2-18 | 6 | <0.001/88.8 | 0.0 (0.0, 0.0) | Ref | Ref | |||
| 18-26 | 3 | 0.003/88.7 | 0.1 (0.0, 0.1) | 9.0 (7.0, 11.7) | <0.001 | |||
| 26-33 | 0.292/10.1 | 0.2 (0.2, 0.3) | 22.1 (17.0, 28.6) | <0.001 | ||||
| ≥ 33 | <0.001/84.8 | 0.4 (-0.0, 0.8) | 52.5 (40.1, 68.9) | <0.001 | ||||
| 18-44 | ≥ 2 | 5 | <0.001/80.4 | 0.0 (0.0, 0.0) | Ref | Ref | mRNA-1273; BNT162b2; Ad26.COV2.S | |
| 45-64 | <0.001/95.7 | 0.1 (0.0, 0.1) | 3.4 (2.4, 5.0) | <0.001 | ||||
| ≥65 | <0.001/98.8 | 0.2 (0.1, 0.3) | 15.2 (10.9, 21.4) | <0.001 | ||||
| 18-49 | 2-34 | 3 | 0.048/50.7 | 0.0 (0.0, 0.0) | Ref | Ref | mRNA-1273; BNT162b2 | |
| 50-64 | <0.001/90.9 | 0.0 (0.0, 0.0) | 2.62 (2.21, 3.11) | <0.001 | ||||
| ≥65 | <0.001/97.1 | 0.1 (0.1, 0.1) | 8.34 (7.19, 9.68) | <0.001 | ||||
| 16-59 | 6-28 | 6 | <0.001/76.3 | 0.0 (0.0, 0.0) | Ref | Ref | BNT162b2 | |
| ≥60 | 3 | <0.001/95.1 | 0.0 (0.0, 0.0) | 24.38 (17.53, 33.91) | <0.001 |